Learn More
3142 Background: The most common serious adverse event associated with thalidomide use for cancer patients has been DVT/PE. METHODS The Research on Adverse Drug Reactions and Reports (RADAR)(More)
2512 Background: Recombinant human erythropoietin (EPO) has been a breakthrough in cancer- and renal insufficiency-associated anemia since 1988. Antibody-mediated PRCA is a rare, serious toxicity(More)
  • 1